Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension

QR Code

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension

Fernanda Pacella, Paolo Turchetti, Valentina Santamaria, David Impallara, Gianpaolo Smaldone, Chiara Brillante, Aloisa Librando, Angela Damiano,&nbsp;Jose Pecori-Giraldi, Elena PacellaDepartment of Sense Organs, University of Rome &quot;Sapienza&quot;, Roma, ItalyBackground:...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Pacella F, Turchetti P, Santamaria V,&nbsp;Impallara D, Smaldone G, Brillante C, Librando A, Damiano A, Pecori-Giraldi J, Pacella E
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2012
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/f551e94c922c4fd6b03d2c12b01783eb
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
par: Ermiş&nbsp;SS
Publié: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
par: Gregory Katz, et autres
Publié: (2010)

Latanoprost in the treatment of glaucoma
par: Alm A
Publié: (2014)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
par: Bhagat P, et autres
Publié: (2014)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
par: Walimbe T, et autres
Publié: (2016)

Results of case-control studies support the association between contact lens use and Acanthamoeba keratitis
par: Pacella E, et autres
Publié: (2013)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
par: Myers JS, et autres
Publié: (2014)

Utility of Ocular Motility Tests in Orbital Floor Fractures with Muscle Entrapment That is Not Detected on Computed Tomography
par: Migliorini R, et autres
Publié: (2021)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
par: David A Godfrey, et autres
Publié: (2009)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
par: Lanzl I, et autres
Publié: (2013)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
par: Sanseau A, et autres
Publié: (2013)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
par: Tao Wang, et autres
Publié: (2021)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
par: Brant Fernandes RA, et autres
Publié: (2019)

Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
par: Natarajan JV, et autres
Publié: (2012)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
par: Figueiredo BP, et autres
Publié: (2013)

Giant cell arteritis: the importance of immediate and appropriate diagnosis and treatment for better prognosis
par: Pacella F, et autres
Publié: (2012)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
par: Dai Woo Kim, et autres
Publié: (2021)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
par: Anne J Lee, et autres
Publié: (2010)

Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
par: M Selim Kocabora, et autres
Publié: (2008)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
par: Anna Galanopoulos, et autres
Publié: (2008)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
par: Douglas J Rhee, et autres
Publié: (2008)

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
par: Pacella E, et autres
Publié: (2013)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
par: Cantor E, et autres
Publié: (2018)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
par: Inoue K, et autres
Publié: (2012)

Relationships between central corneal thickness and optic disc topography in eyes with glaucoma, suspicion of glaucoma, or ocular hypertension
par: Pinakin Gunvant, et autres
Publié: (2008)

Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study
par: Shusaku Ishikawa, et autres
Publié: (2008)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
par: Yelda Buyru &Ouml;zkurt, et autres
Publié: (2009)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
par: Dimitris Papaconstantinou, et autres
Publié: (2009)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
par: Nicholas P Bell, et autres
Publié: (2010)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
par: Laube T, et autres
Publié: (2012)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
par: Sacchi M, et autres
Publié: (2014)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
par: Lerner SF, et autres
Publié: (2019)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
par: Miguel A Teus, et autres
Publié: (2009)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
par: Dorota Pozarowska
Publié: (2010)

Incidence and Risk Factors of Ocular Hypertension/Glaucoma After Descemet Stripping Automated Endothelial Keratoplasty
par: Elalfy M, et autres
Publié: (2021)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
par: Emilio Rintaro Suzuki Jr, et autres
Publié: (2010)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
par: Yoshimi Nakamura, et autres
Publié: (2009)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
par: Andrea Russo, et autres
Publié: (2009)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
par: Syed MF, et autres
Publié: (2011)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
par: Makoto Aihara
Publié: (2010)